Carterra
PrivateLast Round
Series G
Dec 14, 2020
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Carterra is a biotechnology company that provides a high-throughput biosensor platform intended to accelerate the discovery of novel therapeutic candidates.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Services & Consulting, Government Contracts
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Carterra Comparables
Compare Carterra with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nicoya Lifesciences Inc. | 83% | |
| Gator Bio | 82% | |
| NanoTemper Technologies | 80% |
Carterra Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series G | Dec 14, 2020 | ||||
| VC Round | Jan 14, 2020 | ||||
| VC Round | Jan 17, 2018 | ||||
| VC Round | Jul 1, 2014 | ||||
| VC Round | May 30, 2012 |
Carterra Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ballast Point Ventures | Series G, VC Round |
| Telegraph Hill Partners | VC Round, Series G |
| Park City Angels | VC Round |
| Pasadena Angels | VC Round |
| Pfizer | VC Round |
| TCA Venture Group | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 6, 2026
Open roles increased from 0 to 46, representing 53% of headcount.
- Jun 20, 2026
Monthly visitors grew 51% MoM, reaching 11K.
Recent news
Latest coverage and updates
- is_developingOct 13, 2026
Carterra, Inc. announces a research collaboration with AstraZeneca to develop hardware and software for lab-in-the-loop drug discovery, including laboratory systems that generate standardized data at scale and software that makes the data usable in AI and machine-learning workflows, on Oct 14th '26.
- recognized_asOct 12, 2026
William Blair analysts name Carterra, Inc. a Winner in life science tools for enabling AI drug discovery in Utah on Apr 8th '26
- partners_withOct 7, 2026
Carterra, Inc. and AstraZeneca plc collaborate on hardware and software that connect laboratory systems, software, and data infrastructure with AI-driven drug discovery workflows in Utah on Oct 7th '26.
- is_developingOct 7, 2026
On Oct 7th '26, Carterra, Inc. is developing hardware and software with AstraZeneca through a research collaboration to advance AI-driven, lab-in-the-loop drug discovery in Utah.
Carterra Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Carterra's valuation, stock price, and market status.
Is Carterra a public or private company?
Carterra is a private company.
What is the current stock price of Carterra?
Carterra is a private company, so its shares have no public market price. Caplight tracks Carterra's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Carterra worth (valuation)?
Valuation information for Carterra is not publicly available.
Can I buy Carterra stock?
Carterra shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Carterra's last funding round?
Carterra's most recent funding round was Series G on December 14, 2020.
Who are the main investors in Carterra?
Key investors in Carterra include Ballast Point Ventures, Telegraph Hill Partners.
Will Carterra IPO soon?
No public IPO plans have been announced for Carterra.
How can I track Carterra secondary market activity?
Caplight tracks bids, offers, and trades in Carterra's shares on secondary markets.